Stock Analiz

VivoSim Labs, INC. VIVS

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.13Market cap $3M
Open the interactive analysis →

VivoSim Labs, INC. (VIVS) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to September 30, 2026 it had revenue of $135000 and net income of -$10M, a net margin of -7605.9%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -109%.

About VivoSim Labs, INC.

VivoSim Labs, INC. is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $571000 in 2015 to $131000 in 2026, a decline of about 12.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 256% over three years (dilution for shareholders). It spends 3198% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S19.1
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-399.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-9.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-6236.5%
ROIC (5-yr avg.)-108.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$135000$131000$144000$109000$370000$2M$0$2M$3M$5M$4M
Net income-$10M-$14M-$2M-$15M-$17M-$11M-$17M-$19M-$27M-$35M-$38M
Free cash flow-$10M-$11M-$9M-$15M-$13M-$9M-$14M-$15M-$20M-$29M-$31M
EPS (diluted)$-0.44$-0.67$-0.21$-2.41$-2.97$-1.98$-3.66$-4.20$-6.90$-9.60$-11.70
Net margin-7605.9%-10567.2%-1727.8%-13459.6%-4664.6%-763.2%—-852.0%-861.7%-756.1%-908.9%
ROIC——-87.2%-238.6%-81.8%-28.0%-33.9%-63.7%-52.2%-62.5%-48.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does VivoSim Labs, INC. pay a dividend?

Not currently.

Is VivoSim Labs, INC. a good stock to buy?

We do not give buy or sell advice. VivoSim Labs, INC. scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.